These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 11918944)

  • 1. Interferon alfa-2a for melanoma metastases.
    Kirkwood JM; Ibrahim JG; Sondak VK; Ernstoff MS; Ross M
    Lancet; 2002 Mar; 359(9310):978-9. PubMed ID: 11918944
    [No Abstract]   [Full Text] [Related]  

  • 2. Interferon as adjuvant treatment for melanoma.
    Wheatley K; Ives N; Hancock B; Gore M
    Lancet; 2002 Sep; 360(9336):878. PubMed ID: 12243953
    [No Abstract]   [Full Text] [Related]  

  • 3. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
    Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
    Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial.
    Cascinelli N; Belli F; MacKie RM; Santinami M; Bufalino R; Morabito A
    Lancet; 2001 Sep; 358(9285):866-9. PubMed ID: 11567700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of cutaneous melanoma.
    Tsao H; Atkins MB; Sober AJ
    N Engl J Med; 2004 Sep; 351(10):998-1012. PubMed ID: 15342808
    [No Abstract]   [Full Text] [Related]  

  • 6. A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study.
    Sondak VK; Liu PY; Flaherty LE; Fletcher WS; Periman P; Gandara DR; Taylor SA; Balcerzak SP; Meyskens FL
    Cancer J Sci Am; 1999; 5(1):41-7. PubMed ID: 10188060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma.
    Wagner SN; Rebmann V; Willers CP; Grosse-Wilde H; Goos M
    Lancet; 2000 Jul; 356(9225):220-1. PubMed ID: 10963203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
    Bajetta E
    Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604
    [No Abstract]   [Full Text] [Related]  

  • 9. [Interferon for adjuvant therapy in melanoma; although approved, not indicated].
    Groenewegen G; Osanto S; van der Rhee HJ; Punt CJ
    Ned Tijdschr Geneeskd; 2000 Nov; 144(45):2160-2. PubMed ID: 11086492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant high-dose interferon revisited.
    Sondak VK; Flaherty LE
    Cancer J; 2000; 6(3):132-4. PubMed ID: 10882326
    [No Abstract]   [Full Text] [Related]  

  • 11. The use of interferon alfa as adjuvant therapy for advanced cutaneous melanoma: the need for more evidence.
    Kimyai-Asadi A; Usman A
    J Am Acad Dermatol; 2000 Oct; 43(4):708-11. PubMed ID: 11004636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose adjuvant interferon therapy for melanoma.
    Licata AG
    Dermatol Nurs; 1998 Oct; 10(5):334-6. PubMed ID: 9873271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of adjuvant interferon in high risk melanoma patients.
    Dermatol Surg; 2000 Jun; 26(6):607-8. PubMed ID: 10848951
    [No Abstract]   [Full Text] [Related]  

  • 14. [Interferon for adjuvant therapy of melanoma: approved, not indicated].
    Croockewit AJ; Koopmans PP; Lekkerkerker JF
    Ned Tijdschr Geneeskd; 2001 Mar; 145(10):498-9. PubMed ID: 11268915
    [No Abstract]   [Full Text] [Related]  

  • 15. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis.
    Hauschild A; Weichenthal M; Balda BR; Becker JC; Wolff HH; Tilgen W; Schulte KW; Ring J; Schadendorf D; Lischner S; Burg G; Dummer R
    J Clin Oncol; 2003 Aug; 21(15):2883-8. PubMed ID: 12885805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
    Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
    J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma.
    Kirkwood JM; Resnick GD; Cole BF
    Semin Oncol; 1997 Feb; 24(1 Suppl 4):S16-23. PubMed ID: 9122729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of pegylated interferon-alpha-2a in adjuvant therapy of intermediate and high-risk melanomas.
    Loquai C; Nashan D; Hensen P; Luger TA; Grabbe S; Sunderkötter C; Schiller M
    Eur J Dermatol; 2008; 18(1):29-35. PubMed ID: 18086586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant interferon therapy for melanoma.
    Hancock B; Wheatley K; Ives N; Gore M
    J Clin Oncol; 2005 Apr; 23(10):2431; author reply 2431-2. PubMed ID: 15800339
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation on serum 2'-5'oligoadenylate synthetase (2'-5'oligoAS) and beta 2 microglobulin (B2M) in patients with nodal metastases from cutaneous malignant melanoma treated with rIFN-alpha 2A.
    Martinetti A; Seregni E; Belli F; Mazzocchi A; Agresti R; Cascinelli N; Greco M; Bombardieri E
    Anticancer Res; 1998; 18(3B):2027-30. PubMed ID: 9677461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.